Allocations have all been made a while back and was quite heavily subscribed..Some strong institutional support and some sticky high net worth individuals should make for a tight register, especially considering how much of the stock is escrowed until FY18 Audited results.
A good read of the prospectus makes for some interesting observations... Just look at the margins and growth in the CBD business in the US. I noticed on Instagram that Elixinol has a Black Friday to Cyber Monday sale on. (buy one product trial one free) this should lead to a large spike in volume and I would not be surprised to see them hit the CY17 numbers out the ball park.
With Hemp foods also legal for sale here in Australia, you should see a material change and uplift in sales as the products go mainstream, just talking to health food stores you get confirmation sales are picking up and that main stream retailers are starting to look at listing several products next year after the x-mas trading period is over.
There is a still a bit of education to be done to explain to investors the difference between a medical marijuana company and a company selling Hemp and CBD products. In Elixinol we have all 3 covered with the advantage of market penetration and brand awareness. Should make for a strong open and a sustained strength in the share price as the messaging gets out there. This could be one of the better IPO's of the year
